AK
Therapeutic Areas
Lundbeck Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rexulti (brexpiprazole) | Major Depressive Disorder (adjunct), Schizophrenia | Approved/Commercial |
| Vyepti (eptinezumab) | Migraine prevention | Approved/Commercial |
| Trintellix/Brintellix (vortioxetine) | Major Depressive Disorder | Approved/Commercial |
| Sabril (vigabatrin) | Refractory Complex Partial Seizures, Infantile Spasms | Approved/Commercial |
| Abilify Maintena (aripiprazole) | Schizophrenia, Bipolar I Disorder | Approved/Commercial |
| Lu AG09222 (PACAP mAb) | Migraine prevention | Phase 2 |
| Lu AG06466 (MAT2A Inhibitor) | Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) | Phase 1/2 |
| Lu AG13909 (PDE10A Inhibitor) | Schizophrenia | Phase 1 |
Leadership Team at Lundbeck
TG
Thomas Gibbs
Executive Vice President and President
DD
Deborah Dunsire
President and Chief Executive Officer
JL
Johan Luthman
Executive Vice President, Head of Research & Development
CV
Charl van Zyl
Executive Vice President, Head of Commercial Operations
AG
Anders Götzsche
Executive Vice President, Chief Financial Officer
SJ
Steen Juul Jensen
Executive Vice President, Chief Medical Officer
BS
Berit Scheel
Executive Vice President, Head of Legal, Compliance & Sustainability
JK
Judy Krieg
Account Manager
RS
Ronetta Stokes
Person living with migraine
M
Margot
Person living with chronic migraine